Barclays lowered the firm’s price target on HCA Healthcare (HCA) to $390 from $416 and keeps an Overweight rating on the shares post the Q2 report. The firm says the company’s CEO expressed confidence in navigating 2026 and beyond.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- Hold Rating for HCA Healthcare Amid Strong Q2 Results and Future Headwinds Concerns
- HCA Healthcare Reports Strong Q2 2025 Results
- HCA Healthcare: Mixed Financial Performance and Volume Growth Concerns Lead to Hold Rating
- Morning Movers: Intel lower following second quarter earnings
- HCA Healthcare Reports Strong Q2 2025 Financial Results